Elekta's convertible debenture loan 98-01

Elekta's convertible debenture loan 98-01 As announced earlier the last day for conversion of Elekta's convertible debentures is Friday 29 June 2001. Up to now debentures totalling SEK 58,504,285 have been applied for conversion corresponding to 971,832 B-shares. Of these the Swedish Patent and Registration Office has on 8 June registered 550,764 new series B-shares corresponding to an increase in share capital of SEK 2,753,820. After this increase the total number of series B-shares amounts to 27,216,881 and the total number of shares including series A-shares amounts to 28,404,381. This includes applications to convert received until 29 May 2001. Elekta is a world-leading supplier of advanced and innovative radiation oncology and neurosurgery solutions and services for precise treatment of cancer and brain disorders. Elekta's solutions are clinically effective and cost efficient and gentle to the patient. For further information, please contact: Lars Jonsteg, VP Corporate Relations, Elekta AB (publ), tel. +46 8 587 254 82 ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2001/06/12/20040524BIT20660/wkr0006.pdf

About Us

Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm. www.elekta.com


Documents & Links